Stratification of treatment intensity in relapsed pediatric Hodgkin lymphoma

Pediatric Blood and Cancer

Volumn 61, Issue 4, 2014, Pages 579-586

  Harker Murray, Paul D ^a   Drachtman, Richard A ^b   Hodgson, David C ^c   Chauvenet, Allen Russell ^d   Kelly, Kara M ^e   Cole, Peter David ^f,g  

^a Midwest children'S' Cancer Center   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d WEST VIRGINIA UNIVERSITY   (United States)

^e Department of Medicine   (United States)

^f ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^g Children's Hospital   (United States)

Author keywords

Chemotherapy; Hematopoietic cell transplant; Hodgkin lymphoma; Pediatric oncology; Relapse

Indexed keywords

BRENTUXIMAB VEDOTIN; CYTARABINE; ETOPOSIDE; GEMCITABINE;

ALGORITHM; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CHEMORADIOTHERAPY; HODGKIN DISEASE; HUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE;

CHEMOTHERAPY; HEMATOPOIETIC CELL TRANSPLANT; HODGKIN LYMPHOMA; PEDIATRIC ONCOLOGY; RELAPSE;

COMBINED MODALITY THERAPY; HODGKIN DISEASE; HUMANS; NEOPLASM RECURRENCE, LOCAL;

EID: 84893463251     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24851     Document Type: Review

References (47)

1. Nachman JB. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. J Clin Oncol 2002; 20:3765-3771.
2. Hudson MM, Krasin M, Link MP, et al. Risk-adapted, combined-modality therapy with VAMP/COP and response-based, involved-field radiation for unfavorable pediatric Hodgkin's disease. J Clin Oncol 2004; 22:4541-4550.
3. Schwartz CL, Constine LS, Villaluna D, et al. A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: The results of P9425. Blood 2009; 114:2051-2059.
4. Kelly KM, Sposto R, Hutchinson R, et al. BEACOPP chemotherapy is a highly effective regimen in children and adolescents with high-risk Hodgkin lymphoma: A report from the Children's Oncology Group. Blood 2011; 117:2596-2603.
5. Donaldson SS, Link MP, Weinstein HJ, et al. Final results of a prospective clinical trial with VAMP and low-dose involved-field radiation for children with low-risk Hodgkin's disease. J Clin Oncol 2007; 25:332-337.
6. Metzger ML, Weinstein HJ, Hudson MM, et al. Association between radiotherapy vs no radiotherapy based on early response to VAMP chemotherapy, survival among children with favorable-risk Hodgkin lymphoma. JAMA 2012; 307:2609-2616.
7. Mauz-Korholz C, Hasenclever D, Dorffel W, et al. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: The GPOH-HD-2002 study. J Clin Oncol 2010; 28:3680-3686.
8. Ruhl U, Albrecht M, Dieckmann K, et al. Response-adapted radiotherapy in the treatment of pediatric Hodgkin's disease: An interim report at 5 years of the German GPOH-HD 95 trial. Int J Radiat Oncol Biol Phys 2001; 51:1209-1218.
9. Schellong G, Dorffel W, Claviez A, et al. Salvage therapy of progressive and recurrent Hodgkin's disease: Results from a multicenter study of the pediatric DAL/GPOH-HD study group. J Clin Oncol 2005; 23:6181-6189.
10. Kelly KM. Management of children with high-risk Hodgkin lymphoma. Br J Haematol 2012, 157, 3-13.
11. Meyer RM, Gospodarowicz MK, Connors JM, et al. ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma. N Engl J Med 2012; 366:399-408.
12. Hudson MM, Neglia JP, Woods WG, et al. Lessons from the past: Opportunities to improve childhood cancer survivor care through outcomes investigations of historical therapeutic approaches for pediatric hematological malignancies. Pediatr Blood Cancer 2012; 58:334-343.
13. Sureda A, Pereira MI, Dreger P. The role of hematopoietic stem cell transplantation in the treatment of relapsed/refractory Hodgkin's lymphoma. Curr Opin Oncol 2012; 24:727-732.
14. Bierman PJ, Anderson JR, Freeman MB, et al. High-dose chemotherapy followed by autologous hematopoietic rescue for Hodgkin's disease patients following first relapse after chemotherapy. Ann Oncol 1996; 7:151-156.
15. Hodgkin Lymphoma, National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. 2012 [cited 20129-8-2012]; Version 2.2012.
16. Belgaumi A, Al-Kofide AA, Jamil-Malik R, et al. Outcome of second line therapy for pediatric patients with Hodgkin lymphoma who relapse following ABVD based therapy. ASH Annual Meeting Abstracts 2009, 114:2691.
17. James ND, Kingston JE, Plowman PN, et al. Outcome of children with resistant and relapsed Hodgkin's disease. Br J Cancer 1992; 66:1155-1158.
18. Metzger ML, Hudson MM, Krasin MJ, et al. Initial response to salvage therapy determines prognosis in relapsed pediatric Hodgkin lymphoma patients. Cancer 2010; 116:4376-4384.
19. Sieniawski M, Franklin J, Nogova L, et al. Outcome of patients experiencing progression or relapse after primary treatment with two cycles of chemotherapy and radiotherapy for early-stage favorable Hodgkin's lymphoma. J Clin Oncol 2007; 25:2000-2005.
20. Stoneham S, Ashley S, Pinkerton CR, et al. Outcome after autologous hemopoietic stem cell transplantation in relapsed or refractory childhood Hodgkin disease. J Pediatr Hematol Oncol 2004; 26:740-745.
21. Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomised trial. Lancet 1993; 341:1051-1054.
22. Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: A randomised trial. Lancet 2002; 359:2065-2071.
23. Freed J, Kelly KM. Current approaches to the management of pediatric Hodgkin lymphoma. Paediatr Drugs 2010; 12:85-98.
24. Cairo MS, Shen V, Krailo MD, et al. Prospective randomized trial between two doses of granulocyte colony-stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent or refractory solid tumors: A children's cancer group report. J Pediatr Hematol Oncol 2001; 23:30-38.
25. Cole PD, Schwartz CL, Drachtman RA, et al. Phase II study of weekly gemcitabine and vinorelbine for children with recurrent or refractory Hodgkin's disease: A children's oncology group report. J Clin Oncol 2009; 27:1456-1461.
26. Horton TM, Drachtman RA, Chen L, et al. A phase II study of bortezomib with ifosfamide and vinorelbine in pediatric patients with refractory/recurrent Hodgkin disease (HD): A Children's Oncology Group (COG) study. J Clin Oncol 2010; 28, ASCO MEETING ABSTRACTS Jun 14, 2010:9537.
27. Kobrinsky NL, Sposto R, Shah NR, et al. Outcomes of treatment of children and adolescents with recurrent non-Hodgkin's lymphoma and Hodgkin's disease with dexamethasone, etoposide, cisplatin, cytarabine, and l-asparaginase, maintenance chemotherapy, and transplantation: Children's Cancer Group Study CCG-5912. J Clin Oncol 2001; 19:2390-2396.
28. Sandlund JT, Pui CH, Mahmoud H, et al. Efficacy of high-dose methotrexate, ifosfamide, etoposide and dexamethasone salvage therapy for recurrent or refractory childhood malignant lymphoma. Ann Oncol 2011; 22:468-471.
29. Trippett TM, De Alarcon PA, London WB, et al. A pilot study of re-induction chemotherapy with Ifosfamide, and Vinorelbine (IV) in children with refractory/relapsed Hodgkin disease, AHOD00P1 [abstract]. Eur J Haematol 2004; 73:74.
30. Wimmer RS, Chauvenet AR, London WB, et al. APE chemotherapy for children with relapsed Hodgkin disease: A Pediatric Oncology Group trial. Pediatr Blood Cancer 2006; 46:320-334.
31. Moskowitz CH, Yahalom J, Zelenetz AD, et al. High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging. Br J Haematol 2010; 148:890-897.
32. Moskowitz AJ, Yahalom J, Kewalramani T, et al. Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Blood 2010; 116:4934-4937.
33. Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010; 363:1812-1821.
34. Verdeguer A, Pardo N, Madero L, et al. Autologous stem cell transplantation for advanced Hodgkin's disease in children. Spanish group for BMT in children (GETMON), Spain. Bone Marrow Transplant 2000; 25:31-34.
35. Schwartz CL, Friedman DL, McCarten K, et al. Predictors of early response and event-free survival in Hodgkin lymphoma (HL) PET versus CT imaging. J Clin Oncol 2011; 29:8006.
36. Lieskovsky YE, Donaldson SS, Torres MA, et al. High-dose therapy and autologous hematopoietic stem-cell transplantation for recurrent or refractory pediatric Hodgkin's disease: Results and prognostic indices. J Clin Oncol 2004; 22:4532-4540.
37. Gorde-Grosjean S, Oberlin O, Leblanc T, et al. Outcome of children and adolescents with recurrent/refractory classical Hodgkin lymphoma, a study from the Societe Francaise de Lutte contre le Cancer des Enfants et des Adolescents (SFCE). Br J Haematol 2012; 158:649-656.
38. Harris RE, Termuhlen AM, Smith LM, et al. Autologous peripheral blood stem cell transplantation in children with refractory or relapsed lymphoma: Results of Children's Oncology Group study A5962. Biol Blood Marrow Transplant 2011; 17:249-258.
39. Akhtar S, El Weshi A, Rahal M, et al. High-dose chemotherapy and autologous stem cell transplant in adolescent patients with relapsed or refractory Hodgkin's lymphoma. Bone Marrow Transplant 2010; 45:476-482.
40. Shafer JA, Heslop HE, Brenner MK, et al. Outcome of hematopoietic stem cell transplant as salvage therapy for Hodgkin's lymphoma in adolescents and young adults at a single institution. Leuk Lymphoma 2010; 51:664-670.
41. Daw S, Wynn R, Wallace H. Management of relapsed and refractory classical Hodgkin lymphoma in children and adolescents. Br J Haematol 2011; 152:249-260.
42. Baxi SS, Matasar MJ. State-of-the-art issues in Hodgkin's lymphoma survivorship. Curr Oncol Rep 2010; 12:366-373.
43. Ng AK. Review of the cardiac long-term effects of therapy for Hodgkin lymphoma. Br J Haematol 2011; 154:23-31.
44. Hodgson DC. Late effects in the era of modern therapy for Hodgkin lymphoma. Hematol Am Soc Hematol Educ Program 2011; 2011:323-329.
45. Loren AW, Mangu PB, Beck LN, et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline update. J Clin Oncol 2013; 31:2500-2510.
46. Krishnan A, Bhatia S, Slovak ML, et al. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: An assessment of risk factors. Blood 2000; 95:1588-1593.
47. Wadhwa P, Shina DC, Schenkein D, et al. Should involved-field radiation therapy be used as an adjunct to lymphoma autotransplantation? Bone Marrow Transplant 2002; 29:183-189.